U.S. Biologic Therapy Market Size, Share & Forecast 2026–2032

ID: MR-11808 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Biologic Therapy Market
  • ✓Market Size 2024: USD 168.4 billion
  • ✓Market Size 2032: USD 287.5 billion
  • ✓CAGR: 6.9%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
PBM Private Labels Reshape Access: CVS Caremark's Cordavis and Cigna's Quallent now steer commercially insured biologic volume toward private-label adalimumab biosimilars. Manufacturers that treat PBM formulary placement as the primary commercial lever, rather than physician detailing, capture share fastest.
FINDING 02
Originators Retain Value Longer: Conventional wisdom holds that biosimilars will erode originator biologic revenue rapidly after patent expiry. Evidence from Humira shows AbbVie kept substantial share through rebate walls and formulary exclusions, so net price, not volume, drives value decline.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Private-Label Contracts: Biosimilar developers should secure PBM private-label supply agreements and interchangeability designations before the 2026 formulary cycle closes. Originator sponsors should move lifecycle investment into subcutaneous reformulations now, because those formats hold formulary position longer than IV products.

Biologic Therapies in the U.S.: Market Overview

The United States accounts for close to half of global biologic therapy revenue, making it the largest and most profitable biologics market in the world. Spending is driven by premium list prices, rapid adoption of novel monoclonal antibodies and fusion proteins, and a payer system in which Medicare Part B, Medicare Part D, and commercial plans reimburse biologics through separate mechanisms. Unlike European markets, where national authorities set reference prices, American net prices are negotiated privately among manufacturers, pharmacy benefit managers, and insurers.

Structurally, the market divides between physician-administered infused products billed under Part B at average sales price plus 6 percent and self-administered subcutaneous products dispensed through specialty pharmacies under Part D or commercial pharmacy benefits. This split determines which intermediaries capture margin and explains why identical molecules carry very different net prices across channels. Total U.S. biologic spending reached an estimated USD 168.4 billion in 2024, with specialty pharmacy channels now carrying the majority of self-administered volume.

Growth Drivers in U.S. Biologic Therapies

Demographic aging is the most durable driver. Adults aged 65 and older represented about 18 percent of the population in 2022 according to the U.S. Census Bureau, and this cohort accounts for the majority of biologic prescriptions in rheumatology, oncology, and ophthalmology. The final baby boomers turn 65 in 2029, extending Medicare-eligible biologic demand well beyond the forecast window and sustaining Part B infusion volumes through 2032.

Oncology pipeline expansion provides the second driver. Checkpoint inhibitors such as Merck's Keytruda and Bristol Myers Squibb's Opdivo continue gaining indications in earlier-stage disease, while bispecific T-cell engagers are moving into second-line lung and lymphoma settings. Biosimilar uptake under the Biologics Price Competition and Innovation Act of 2009 adds a third driver, as Humira biosimilars launched in 2023 widened treated populations at lower net cost.

Market Restraints and Entry Barriers

Medicare price negotiation under the Inflation Reduction Act is the most significant new restraint. Enbrel and Stelara, both biologics, were among the first ten drugs selected for negotiated Maximum Fair Prices effective January 1, 2026. The statute grants biologics a 13-year window from licensure before negotiation eligibility, compared with 9 years for small molecules, a distinction that now shapes sponsor timing and lifecycle decisions.

Entry barriers for newcomers center on the 340B Drug Pricing Program, PBM rebate structures, and cold-chain specialty distribution. Hospitals and federally qualified health centers buying through 340B capture discounts that depress realized pricing, while specialty pharmacies such as Optum Specialty and CVS Specialty control dispensing for many subcutaneous products. Entrants also face prior authorization requirements that often delay first fill by several weeks.

Market Opportunities in U.S. Biologics

Biosimilar expansion creates the nearest opening. FDA's draft guidance on biosimilar development moves away from routine comparative efficacy studies, substantially lowering development cost per molecule. Ustekinumab and aflibercept generated more than USD 10 billion in combined U.S. originator sales in 2023, making them the largest near-term biosimilar pools for entrants with contracting capacity.

Subcutaneous reformulation and cell and gene therapy represent the second opportunity. The Centers for Medicare and Medicaid Services' Cell and Gene Therapy Access Model, launched in 2025 for sickle cell disease, establishes outcomes-based payment for one-time therapies and provides a template for other indications. Entrants with at-home and ambulatory infusion capability can address the shift of infused biologic volume out of hospital outpatient settings.

Market at a Glance

MetricValue
Market Size 2024USD 168.4 billion
Market Size 2032USD 287.5 billion
Growth Rate (CAGR)6.9%
Most Critical Decision FactorNet price after PBM rebates and Medicare negotiation
Largest RegionSouth
Competitive StructureConcentrated originator oligopoly with a growing biosimilar fringe

Leading Market Participants

  • Amgen
  • AbbVie
  • Johnson & Johnson
  • Pfizer
  • Merck & Co.
  • Bristol Myers Squibb
  • Genentech
  • Regeneron
  • Eli Lilly
  • Sanofi

Regulatory and Policy Environment

The Public Health Service Act Section 351 governs biologic licensure through Biologics License Applications reviewed by FDA's Center for Biologics Evaluation and Research. Standard review runs ten months after a 60-day filing period, while priority review shortens the total timeline to roughly eight months. PDUFA VII fee commitments for fiscal years 2023 through 2027 fund reviewer capacity, and the Biologics Price Competition and Innovation Act grants reference products twelve years of exclusivity.

Pricing and coverage policy sits with CMS and Congress. The Inflation Reduction Act caps Medicare Part D out-of-pocket spending at USD 2,000 in 2025, shifting liability toward plans and manufacturers, and raises Part B biosimilar add-on payments to average sales price plus 8 percent for qualifying products through 2027. The Orphan Drug Tax Credit under Internal Revenue Code Section 45C provides 25 percent of qualified clinical testing expenses for rare-disease biologics.

Long-Term Outlook for U.S. Biologics

By 2032 the U.S. biologic therapy market is projected to reach USD 287.5 billion, growing at a 6.9 percent CAGR from the 2025 base year. Growth will shift away from originator IV products and toward biosimilars, subcutaneous formats, and specialty oncology agents, with net revenue expanding more slowly than gross volume as rebates and negotiated prices deepen.

Expect consolidation among specialty pharmacies and PBM-owned channels, along with a higher share of biologic dispensing in home and ambulatory settings. Negotiated Medicare prices from later IRA selection cycles will further compress margins on mature originators, pushing sponsors toward pipeline replacement and acquisition of late-stage biotechnology assets.

Frequently Asked Questions

Sponsors file a Biologics License Application with FDA's Center for Biologics Evaluation and Research under PHS Act Section 351. Standard review takes about twelve months from submission, including the 60-day filing period.
Developers file a 351(k) application demonstrating biosimilarity to a licensed reference product. Interchangeability designation requires additional evidence, and FDA's recent draft guidance seeks to reduce that burden.
Part B governs infused products reimbursed at average sales price plus 6 percent, while Part D and commercial benefits govern self-administered products. Net pricing in the latter channel depends heavily on PBM rebate negotiations.
Biologics become eligible for IRA negotiation 13 years after licensure, which gives sponsors a longer exclusive revenue window than small molecules. Sponsors must model negotiated prices into lifecycle and launch decisions from the outset.
Ustekinumab and aflibercept biosimilars address the largest near-term pools, with combined U.S. originator sales above USD 10 billion in 2023. Entrants with established PBM contracting capacity are best placed to capture share.

Market Segmentation

By Product Type
  • Monoclonal Antibodies
  • Therapeutic Proteins
  • Biosimilars
  • Vaccines
  • Cell and Gene Therapies
By Therapeutic Area
  • Oncology
  • Immunology
  • Metabolic Disorders
  • Neurology
  • Ophthalmology
By Distribution Channel
  • Specialty Pharmacies
  • Hospital Pharmacies
  • Home Infusion
  • Physician Offices
  • Retail Pharmacies

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Biologic Therapy Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Monoclonal Antibodies
4.2 Therapeutic Proteins
4.3 Biosimilars
4.4 Cell and Gene Therapies
4.5 Others
Chapter 05 Therapeutic Area Insights
5.1 Oncology
5.2 Immunology
5.3 Metabolic Disorders
5.4 Neurology
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Specialty Pharmacies
6.2 Hospital Pharmacies
6.3 Home Infusion
6.4 Physician Offices
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Amgen
7.2.2 AbbVie
7.2.3 Johnson & Johnson
7.2.4 Pfizer
7.2.5 Merck & Co.
7.2.6 Bristol Myers Squibb
7.2.7 Genentech
7.2.8 Regeneron
7.2.9 Eli Lilly
7.2.10 Sanofi
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.